ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Prostate Cancer

Prostate Cancer

The incidence of early-stage prostate cancer in men 50 years and older continued a decline reported earlier, with lower rates in 2013 compared to 2012. This is a likely result of the October 2011 recommendation from the USPSTF against routine PSA testing in all men.

In this interview we discuss PSA screening for prostate cancer, the compromised results of the PLCO trial, and more.

Androgen-deprivation therapy (ADT) is associated with shortened survival in African American men with favorable-risk prostate cancer, according to a new study. The results suggest ADT should be reserved for men with higher risk disease.

Determining the presence of AR-V7 in prostate cancer patients could potentially save the US healthcare system $150 million each year by preventing unnecessary treatment.

Outcomes after salvage radiotherapy are affected by variables related to prostatectomy for men with prostate cancer, but its use at lower PSA levels may improve outcomes.

Robot-assisted and open radical surgeries for prostate cancer have similar outcomes for patients at 3 months, according to clinical trial results.

A randomized phase III trial found that a hypofractionated radiotherapy regimen was not superior to, but generally equivalent to a conventional radiotherapy scheme in men with localized prostate cancer.

Pages

Subscribe to Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.